Skip to main content
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
Abstract
This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.